SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

NATCO Pharma reports 21% fall in Q1 consolidated net profit

09 Aug 2019 Evaluate

NATCO Pharma has reported results for first quarter ended June 30, 2019.

The company has reported 21.69% fall in its net profit at Rs 147.70 crore for the quarter under review as compared to Rs 188.60 crore for the same quarter in the previous year. Total income of the company decreased by 12.02% at Rs 485.10 crore for Q1FY20 as compared Rs 551.40 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported a fall of 21.15% in its net profit at Rs 142.80 crore for the quarter under review as compared to Rs 181.10 crore for the same quarter in the previous year. Total income of the company decreased by 10.65% at Rs 513.30 crore for Q1FY20 as compared Rs 574.50 crore for the corresponding quarter previous year.

Natco Pharma Share Price

1118.95 31.25 (2.87%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×